primary antibody anti p2y 6 r  (Alomone Labs)

Journal: Purinergic Signalling

Article Title: Proteasomal-dependent endothelial P2Y 6 receptor downregulation as an adaptive mechanism limiting monocyte adhesion during intestinal schistosomiasis

doi: 10.1007/s11302-026-10141-x

Figure Lengend Snippet: Endothelial P2Y 6 R mRNA and protein levels are reduced during schistosomiasis. A. Immunocytochemistry staining of cultured mesenteric endothelial cells from control (top line) and infected (bottom line) groups using anti-P2Y 6 R antibody (1:500, overnight), followed by Alexa Fluor 488 secondary antibody (1:300, 1 h, green) and nuclear fluorescence using DAPI (blue) (scale bar = 20 μm; × 400) (see methods). B. The fluorescence intensity was quantified and then expressed as arbitrary units (a.u.). P2Y 6 R mRNA levels were lower in the infected (gray bars) than in the control (white bars) group. C. The P2Y 6 R mRNA levels were normalized by the endogenous gene β-actin. Data were expressed as mean and SEM of n independent cultures performed with different animals for each condition. ***p < 0.001, **p < 0.01 (unpaired t -test, n = 3–4 animals for each group)

Article Snippet: Primary antibody anti-P2Y 6 R (#APR-011) was obtained from Alomone Labs.

Techniques: Immunocytochemistry, Staining, Cell Culture, Control, Infection, Fluorescence

Journal: Purinergic Signalling

Article Title: Proteasomal-dependent endothelial P2Y 6 receptor downregulation as an adaptive mechanism limiting monocyte adhesion during intestinal schistosomiasis

doi: 10.1007/s11302-026-10141-x

Figure Lengend Snippet: Endothelial P2Y 6 R expression is increased by proteosome inhibition during schistosomiasis. A. Immunocytochemistry staining of cultured mesenteric endothelial cells from basal (top line) MG132 1 µM, 1 h (middle line) or MG132 1 µM, 6 h (bottom line) using anti-P2Y 6 R antibody (1:500, overnight) followed by Alexa Fluor 488 secondary antibody secondary antibody (1:300, 1 h, green) and nuclear fluorescence using DAPI (blue) (scale bar = 20 μm; × 400) (see methods). B. The fluorescence intensity was quantified for all groups and then expressed as arbitrary units (a.u.). C . ROS was quantified colorimetrically using NBT. D . Lipid peroxidation was quantified by the production of malondialdehyde (MDA) in reaction with thiobarbituric acid. Data were expressed as the mean and SEM of n independent cultures in triplicate for each condition. **p < 0.01 ( B , One-way ANOVA followed by Tukey’s multiple comparisons test, n = 3 animals for each group); ***p < 0.001; **p < 0.01 (C, D, unpaired t -test, n = 3 animals for each group). ROS = reactive oxygen species; TBARS = thiobarbituric acid reactive species

Article Snippet: Primary antibody anti-P2Y 6 R (#APR-011) was obtained from Alomone Labs.

Techniques: Expressing, Inhibition, Immunocytochemistry, Staining, Cell Culture, Fluorescence

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Mechanistic diagram of P2Y 14 R.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Representative chemical structures of known P2Y 14 R antagonists.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Structural superposition of the five P2Y 14 R complexes.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Distribution of docking scores between known antagonists and decoy compounds using SP and XP scoring modes of Glide docking for five P2Y 14 R complexes.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using DrugRep.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using Glide XP docking and MM/GBSA minimizations.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The potential P2Y 14 R antagonists with the highest ranking from DrugBank, which include both approved and experimental drugs, were predicted using (a) AutoDock Vina of DrugRep and (b) Glide XP docking followed by MM/GBSA minimizations.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: (a) Per-residue interaction decomposition of the antagonist-P2Y 14 R binding free energy for P2Y 14 R· 7 and P2Y 14 R· DB07565 . (b) The 3D-cocrystal structure of P2Y 14 R with DB07565 . (c) Schematic representation of the GPCR-membrane complex.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques: Residue, Binding Assay, Membrane

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The DCCM analysis of apo and antagonistic P2Y 14 R system.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The free energy landscape analysis of apo-P2Y 14 R system and corresponding conformation in local energy minima.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The free energy landscape analysis of (a) P2Y 14 R· 7 and (b) P2Y 14 R· DB07565 system and corresponding conformations in local energy minima.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The in vitro biological testing of DB07565 . (a) In vitro P2Y 14 R antagonistic activity of DB07565 (N = 3). (b) The effect of DB07565 on cell viability of HT-29 cells (N = 5).

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques: In Vitro, Activity Assay